The effect of Kuntai capsules combined with fenmutong on patients with premature ovarian failure
Objective:To evaluate the clinical efficacy of Kuntai capsules combined with fenmotiong in the treatment of premature ovarian failure,and its role in restoring or improving ovarian function.Methods:82 patients with premature ovarian failure admitted to the Nanchang People's Hospital between January 2021 and October 2023 were selected.They were randomly divided into two groups,the observation group and the control group,with 41 patients each.Patients in the control group were treated with fenmotiong,with a treatment cycle of 28 days per course.In the first 14 days of the treatment cycle,the patient took brick red tablets containing 2 mg of estradiol orally,1 tablet/time,once a day.During the 15～28 d treatment period,the patients were given gray tablets containing 1 mg of estradiol and 10 mg of dydrogesterone orally,1 tablet/time,once a day.The observation group was treated with Kuntai capsules on the basis of the control group,4 capsules/time,taken orally after meals,3 times/day,and both groups were treated for 3 months.The levels of sex hormones,ovarian blood flow,ovarian color doppler ultrasound indices,serum cytokines,and adverse reactions were compared between the two groups.Results:There was no significant difference in sex hormone levels between the two groups before treatment(P＞0.05).After treatment,the levels of estradiol in both groups increased,while those of follicle-stimulating and luteinizing hormones decreased(P＜0.05).After treatment,the estradiol levels in the observation group were significantly higher than those in the control group,whereas the levels of follicle-stimulating hormone and luteinizing hormone were significantly lower than those in the control group(P＜0.05).There was no significant difference in ovarian blood flow between the two groups before treatment(P＞0.05).After treatment,the peak systolic blood flow velocity in both groups increased,whereas the resistance index and pulsatility index decreased(P＞0.05).After treatment,the peak systolic blood flow velocity in the observation group was significantly higher than that in the control group,whereas the resistance index and pulsatility index were significantly lower in the observation group than in the control group(P＜0.05).Before treatment,there was no significant difference in the indices of ovarian color Doppler ultrasound between the two groups(P＞0.05).After treatment,the endometrial thickness,number of antral follicles,and ovarian volume of the two groups increased,and the observation group was significantly higher than that of the control group(P＜0.05).There was no significant difference in the serum cytokine levels between the two groups before treatment(P＞0.05).After treatment,the helper T cells 17 in the two groups were lower than before treatment,whereas the regulatory T cells and transforming growth factor-β1 were higher than before treatment(P＞0.05).After treatment,the helper T cells 17 in the observation group were lower than those in the control group,while the regulatory T cells and transforming growth factor-β1 were significantly higher than those in the control group,and the difference was statistically significant(P＜0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P＜0.05).Conclusions:The combined application of Kuntai Capsule and Fenmotiong in the treatment of patients with premature ovarian failure showed remarkable effects,which can improve the clinical symptoms of patients,regulate the level of sex hormones,restore ovarian function,and have good safety and tolerance.This study provides a new and effective method for the treatment of premature ovarian failure.
万方数据
维普
